<DOC>
	<DOCNO>NCT00379574</DOCNO>
	<brief_summary>Diffuse large B-cell lymphoma prevalent non-Hodgkin 's lymphoma . Recently clinical result improve new drug new modality cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) every 2 week . Bortezomib well known effective multiple myeloma try malignancy include lymphoma . The investigator incorporate Bortezomib CHOP every 2 week improve clinical efficacy diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Bortezomib Plus CHOP Every 2 Weeks Advanced Stage DLBCL</brief_title>
	<detailed_description>Intended number patient : 63 patient total - Phase I : 9 patient 3 level - Phase II : 50 patient plus 3 patient Phase I MTD level - Plus 4 patient : consider 5 % follow-up loss rate Study design methodology : For phase I , 9 patient ; 3 level bortezomib ( 1.0 , 1.3 1.6 mg/m2 ) , 3 patient dose level . If escalation bortezomib beyond 1.0 mg/m2 possible , trial stop . For phase II , 53 patient ( 3 phase I MTD level ) ; Reject complete response rate equal le 12/19 37/53 Simon two-stage optimal phase II design . Treatments : - Bortezomib : For phase I , 3 dose level ( 1.0 , 1.3 1.6 mg/m2 ) , day 1 4 , every 2 week . For phase II , suggest dose Bortezomib phase I , day 1 4 , every 2 week . - CHOP2 : cyclophosphamide 750mg/ m2 day 1 , vincristine 1.4 mg/ m2 ( max . 2 mg ) day 1 , doxorubicin 50 mg/ m2 day 1 , prednisolone 100 mg day 1-5 , every 2 week . - G-CSF : Lenograstim 5 microgram/kg subcutaneously day 4-13 every 2 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Histologically confirm DLBCL Age 70 year less Previously untreated Performance status : ECOG 02 Advanced stage : stage III , IV , noncontiguous stage II Measurable disease : 1 cm spiral CT Normal liver function Platelet count le 75,000/microL within 14 day enrollment . Absolute neutrophil count le 1,500/microlL within 14 day enrollment . Cr 2.0 mg/dL and/or calculate measured creatinine clearance le 50 mL/min within 14 day enrollment . Peripheral neuropathy Grade 2 worse within 14 day enrollment . Hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Other investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study . Uncontrolled severe cardiovascular disease , include MI within 6 month enrolment , New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>diffuse large B-cell lymphoma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>CHOP</keyword>
	<keyword>Lenograstim</keyword>
</DOC>